$IRD

SCHACHLE JOSEPH K sold $14K of IRD

SCHACHLE JOSEPH K (Chief Operating Officer) sold 4,644 shares of Opus Genetics, Inc. (IRD) at $2.94 on 2026-07-23.

Original reporting
SEC EDGAR · SCHACHLE JOSEPH K
Published Jul 27, 2026, 8:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 27, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$IRD
Neutral
medium confidence
Mentioned
$IRD
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IRDNeutralLow
01

Why it matters

Traders may monitor insider activity as a sentiment signal, but this disclosure alone does not provide new business or financial guidance.

02

Market read

A COO open-market sale at $2.94/share is newly disclosed, offering a modest sentiment datapoint rather than a catalyst.

03

What to watch

The filing does not disclose motivations, and the article provides only one sale transaction without context on prior insider activity or total holdings changes over time.

Relevance 3/10Novelty 4/10Timing: new Form 4 disclosure filed after-hours on 2026-07-27

Background

The article is a primary-source SEC Form 4 insider transaction for Opus Genetics, Inc.

Company-level read

Ticker impact

$IRDNeutralMedium confidence
Context

Opus Genetics COO Joseph K. Schach sold 4,644 shares in an open-market transaction at $2.94/share, per Form 4 filed July 27.

Expected impact

Limited near-term impact; any reaction is likely sentiment-driven and short-lived.

Evidence & confidence

Form 4 provides a fresh datapoint on insider selling, but insider sales are common and the article lacks any accompanying operational or guidance catalyst.

Market effects

No sector-level read-across; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

The absence of a 10b5-1 plan does not necessarily imply bearish intent; sales can be driven by diversification or tax planning.

Key entities

  • Opus Genetics, Inc.

    Company whose insider transaction is disclosed on Form 4.

  • SCHACHLE JOSEPH K

    Chief Operating Officer who executed the open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IRDMedAI 8/10

Opus Genetics (IRD) Reports Five Early BIRD-1 Responses. Is Phase 3 Planning Justified?

Opus Genetics (NASDAQ: IRD) reported that all five participants in its BIRD-1 trial showed clinically meaningful improvements in visual function. The Phase 1/2 trial included patients with Best vitelliform macular dystrophy and autosomal recessive bestrophinopathy, with no serious adverse events. The company is considering Phase 3 planning, with FDA alignment on potential endpoints. Higher-dose cohort dosing is expected to finish in Q4 2026, with topline results in Q2 2027.

$IRDMedAI 8/10

Opus Genetics, Inc. (IRD): OPGx-BEST1 Gene Therapy Phase 1/2 Study Low Dose Cohort 1 3-month Results September 9, 2026

Opus Genetics, Inc. (IRD) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 OPGx-BEST1 Gene Therapy Phase 1/2 Study Low Dose Cohort 1 3-month Results September 9, 2026 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looki